We wish to inform that a routine current Good Manufacturing (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at the Sterile Product Division facility (SPD) of OneSource Specialty Pharma Limited from June 22, 2026 to June 30, 2026. The inspection has concluded with one observation. The Company will respond to the observation comprehensively to FDA within the stipulated time frame.